Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, announced that its Malaysian arm, Biocon Sdn. Bhd., has crossed a significant healthcare milestone, supplying over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health.

This accomplishment highlights Biocon Biologics’ commitment to enhancing diabetes care and ensuring affordable insulin access in Malaysia.

Since entering the Malaysian market in 2016, Biocon Biologics has served more than 345,000 diabetes patients through its reliable supply of rh-insulin. The company's efforts have been instrumental in transforming diabetes management in the region.

Biocon’s success in Malaysia stems from a strong public-private partnership model with the Malaysian government. This collaboration has focused on innovation, local talent development, and achieving insulin self-sufficiency. In addition, Biocon Biologics works closely with Duopharma Marketing Sdn. Bhd., a subsidiary of Duopharma Biotech Berhad, Malaysia’s leading pharma company, to expand its reach across the country.

Biocon Biologics has established a state-of-the-art Center of Excellence for insulins at its manufacturing facility in Johor, Malaysia. Since 2011, the company has invested around USD 600 million in this facility, which features end-to-end capabilities to manufacture regular, basal, and rapid-acting insulins in various formats, including cartridges and insulin delivery devices.

The Malaysia Book of Records has officially recognised Biocon Sdn. Bhd., as the country’s first and largest integrated insulin manufacturer, further underlining its contribution to Malaysia’s healthcare infrastructure.

Globally, Biocon Biologics is ranked among the top three players for rh-Insulin and Insulin Glargine. The company is dedicated to reaching ‘1 in 5’ insulin-dependent individuals worldwide and has already delivered 9.2 billion doses of insulin-based products globally.

: HDB Financial IPO Allotment Status Today; Shares to Be Credited on July 1!

Biocon Biologics' achievement in Malaysia marks a significant step toward global insulin access and affordability. With strong partnerships and world-class manufacturing, the company continues to lead innovation in diabetes care.

: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.